לפגישת ייעוץ וטיפול התקשרו: 052-5342757


שירותי חוות דעת משפטית רפואית בתחומים הבאים:
1. חוות דעת רפואית משפטית התעמרות בעבודה.
2. חוות דעת רפואית משפטית כנגד חברות הביטוח.
3. חוות דעת רפואית משפטית בענייניי נזיקין.

תחומי עיסוק עיקריים:
✔ טיפול בחרדה
✔ דיכאון עמיד לטיפול תרופתי, הפרעות במצב רוח
✔ או סי די (OCD) – תסמונת כפייתית טורדנית
✔ הפרעת קשב וריכוז
✔ טיפול בהפרעות פסיכוטיות
✔ פסיכותרפיה

פרסומים מדעיים שלי
מאמרים רפואיים שלי אשר פורסמו בכתבי עת רפואיים בינלאומיים. פרקים בספרים וספר שכתבתי

מאמרים רפואיים
1. RD. Strous, M. Shtain, H. Oselka-Goren, M. Lustig, R. Stryjer
M. zerzion, Y. Baruch, J. Chelben.
Anticipatory reactions of psychiatric inpatients to the year 2000.
J Nerv Ment Dis. 2000; 188:786-8.
2. R. Stryjer, RD. Strous, F. Bar, AM. Ulman, JM. Rabey.
Segmental dystonia as the sole manifestation of carbamazepine toxicity.
Gen Hosp Psychiatry. 2002;24:114-5.
3. R. Stryjer, RD .Strous, Y. Baruch, JM.Rabey.
Donepezil management of schizophrenia with associated dementia.
J Clin Psychopharmacolol. 2002:22;226-9
4. R. Stryjer, RD. Strous, F. Bar, E .Werber, G .Shaked, Y. Buhiri,
M .Kotler, A. Weizman, JM .Rabey
Beneficial effect of donepezil augmentation for the management of
comorbid schizophrenia and dementia.
Clin Neuropharmacol. 2003;60:133-41.
5. RD. Strous, R .Maayan, R. Lapidus, R. Stryjer, M. Lustig, M. Kotler,
A. Weizman
Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
Arch Gen Psychiatry. 2003;60:133-41.
6. R. Stryjer, RD. Strous, G. Shaked, F. Bar, B. Feldman, M. Kotler,
L. Polak , S .Rozenzcwaig, A .Weizman.
Amantadine as augmentation therapy in the management of treatment –
resistant depression.
Int Clin Psychopharmacol. 2003; 18:93 -6.
7. RD .Strous, R .Stryjer, N .Keret, M. Bergin, M. Kotler.
Reactions of psychiatric and medical inpatients to terror and security instability in Israel .
J Nerv Ment Dis. 2003;191:126-9.
8. R. Styrjer, RD. Strous, F. Bar, M .Poyurovsky, A .Weizman, M. Kotler
Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone.
Clin Neuropharmacol. 2003; 26:137-41.
9. P. Stopkova, T. Saito, DF. Papolos, R. Stryjer, RD. Strous,
MH.Lachman
Polymorphism screening of PIP5K2A: A candidate gene for 10p-linked
psychiatric disorders.
Am J Med Genet .2003:15;123B(1):50-8.
10. L.Pollak, C. Klein, R. Stryjer , V. Kossych, JM. Rabey
Anxiety in the first attack of vertigo.
Otolaryngol Head Neck Surg. 2003; 128(6):829-34.
11. L. Pollak, C. Klein, R. Stryjer, M. Kushnir, J.Teitler.
Phobic postural vertigo: A new proposed entity.
J Isr Med Assoc. 2003;10:720-723.
12. RD. Strous, R. Stryjer, M. Zerzion, M. Weiss, F .Bar.
Accent echoing: a newly described imitation phenomena of psychosis?
Isr Med Assoc J. 2003;5:61-2.
13. R. Shiloh, L. Bodinger, N. Katz, M. Sigler, R. Stryjer, H. Hermesh, H.Munitz, A .Weizman
Lower corneal temperature in neuroleptic-treated vs. drug-free schizophrenia patients.
Neuropsychobiology. 2003;48(1):1-4.
14. R. Stryjer, RD .Strous, F .Bar, G. Shaked, R .Shiloh, S .Rozencweig, D. Grupper, N .Buchman, M. Kotler, JM. Rabey, A .Weizman
Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
Human psychopharmacol Clinical and Experimental. 2004;19(5):343-346.
15. I. Reznik, I.Yavin, R. Stryjer , B. Spivak , N. Gonen , RD Strous ,
A. Weizman, R. Mester , M. Kotler.
Clozapine in the treatment of obsessive-compulsive symptoms in chizophrenia: A case series study.
Pharmachopsychiatry.2004; 37(2):52-6
16. E. Nahshoni, N. Manor, F. Bar, R. Stryjer, G. Zalsman, A. Weizman.
Alterations in QT dispersion in medicated schizophrenia patients following electroconvulsive therapy.
European Neuropsychopharmacol. 2004; 14(2):121-5
17. RD. Strous, R. Strjyer, D .Ofir, M. Weiss, F. Bar, Y. Baruch, M. Kotler
DSMIV self-evaluation by psychiatrists.
Israel J Psychiatry Relat Sci . 2004;41(3):197-207.
18. R. Stryjer , D. Grupper, RD Strous, M. Poyurovsky, A. Weizman
Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient.
European Psychiatry .2004;19(4):237-8
19. R. Stryjer, C. Klein, T. Treves, T. Prohorof, JM. Rabey .
The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson’s disease patients.
Acta Neurologica Scand. 2005; 111(2):
20. R. Shiloh, H. Munitz, S. Portuguese, R. Gross-Isseroff, M. Sigler, L.Bodinger, N. Katz,
R. Stryjer, H. Hermesh, A. Weizman.
Corneal temperature in schizophrenia patients
International Journal of Neuro psychopharmacology. 2005;1:1-11.
21. K. Schwartz, I.Iancu, R. Stryjer, J. Chelben, M. Kotler, A. Weizman,
Rehavi.
Reduced platelet vesicular monoamine transporter density in smoking schizophrenia patients
Eur Neuro psychopharmacology. 2005; 15(5):557-61.
22. L. Pollak, R. Stryjer, M. Kushnir, S. Flechter
Approach to bilateral benign paroxysmal positioning vertigo
Am J Otolaryngol. 2006; 27(2):91-5.
23. L. Pollak, M. Kushnir, R. Stryjer
Diagnostic value of vestibular evoked myogenic potentials in cerebellar and lower-brainstem strokes.
Neuro physiol Clin. 2006;36(4):227-33.
24. RD. Strous,R.Stryjer , R.Maayan,G. Gal , D. Viglin,E. Katz ,D. Eisner , A. Weizman.
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Psychoneuroendocrinology. 2007; 32(2): 96-105.
25. R. Shiloh ,H. Munitz, R.Stryjer, A. Weizman.
A significant correlation between ward temperature and the severity of symptoms in schizophrenia Inpatients-A longitudinal study.
Eur Neuro psychopharmacol ;2007; 17(6-7): 478-82
26. M.Poyurovsky,S. Faragian,A. Pashinian, A.Levi, A.Viosburd, R.Stryjer, R.Weizman, C. Fuchs , A.Weizman .
Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder.
J Neuro psychiatry Clin Neurosci. 2007 Spring;19(2):145-50
27. In vivo occipital-frontal temperature-gradient in schizophrenia patients and its possible association with psychopathology: a magnetic resonance spectroscopy study.
Shiloh R, Kushnir T, Gilat Y, Gross-Isseroff R, Hermesh H, Munitz H, R Stryjer,Weizman A, Manor D.
Eur Neuro psychopharmacol. 2008 Aug;18(8):557-64. 2008 Jun 12.
28. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study.
Stryjer R, Spivak B, Strous RD, Shiloh R, Harary E, Polak L,
Birgen M, Kotler M, Weizman A.
Clin Neuro pharmacol. 2009 Mar-Apr;32(2):82-4
29. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study.
Avital A, Gross-Isseroff R, Stryjer R, Hermesh H, Weizman A, Shiloh R.
Eur Neuro psychopharmacol. 2009 Jul;19(7):476-82. Epub 2009 Apr 2.
30. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients.
Shiloh R, Schapir L, Bar-Ziv D, Stryjer R, Konas S, Louis R, Hermesh H,
Munitz H, Weizman A, Valevski A.
Eur Neuro psychopharmacol. 2009 Sep;19(9):654-8. Epub 2009 Jun 2.
31. Altered thermoregulation in ambulatory schizophrenia patients: a naturalistic study.
Shiloh R, Weizman A, Stryjer R, Kahan N, Waitman DA.
World J Biol Psychiatry. 2009;10(2):163-70.
32. Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study.
Stryjer R, Timinsky I, Reznik I, Weizman A, Spivak B.
Clin Neuropharmacol. 2009 Sep-Oct;32(5):290-2
33. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study.
Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B.
Clin Neuro pharmacol. 2010 Sep-Oct;33(5):219-22.
34. Response to deep TMS in depressive patients with previous electroconvulsive treatment.
Rosenberg O, Zangen A, Stryjer R, Kotler M, Dannon PN.
Brain Stimul. 2010 Oct;3(4):211-7. 2009 Dec 30
35. Prevalence of Dementia in an Elderly illiterate Native Mexican Population of indigenous Origin.
Stryjer R, Spivak B, Shiloh R, Polak L, Weizman A, Rabey J.M
Journal of public health and epidemiology Vol.3 (11).pp.556-559, 16 November, 2011
36. Beliefs and emotional reactions in patients with benign paroxysmal positional vertigo: a longitudinal study.
Pollak L, Segal P, Stryjer R, Stern HG.
Am J Otolaryngol. 2012 Mar;33(2):221-5. Epub 2011 Aug 26.
37. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia.
Stryjer R, Ophir D, Bar F, Spivak B, Weizman A, Strous RD.
Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4.
38. ESCITALOPRAM IN THE TREATMENT OF PATIENTS SUFFERING FROM
SCHIZOPHRENIA AND OBSESSIVE COMPULSIVE DISORDER – AN OPEN-LABEL, PROSPECTIVE STUDY.
R. Stryjer ,M.D. Y.Dambinsky M.D., I.Timinsky M.D, T. Green M.D., M.Kotler,A. Weizman M.D, B. Spivak M.D.
Journal International Clinical Psychopharmacology. 2013
39. Amantadine augmentation therapy for obsessive compulsive patients to SSRIs-an open label study.
R. Stryjer, et al.
Clin Neuropharmacol. 2014
40. Fatigue during an episode of benign paroxysmal positional vertigo.
Pollak L, R. Stryjer
Eur Arch Otorhinolaryngol 2014.
41. Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study.Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study.
Tiosano S, Farhi A, Watad A, Grysman N, Stryjer R, Amital H, Comaneshter D, Cohen AD, Amital D.
Epidemiol Psychiatr Sci. 2016 Jul 26:1-6.
42. Magnetic resonance brain imaging in patients with visual vertigo.
Pollak L, Osherov M, Berkovitz N, Beckerman I, Stryjer R, Tal S.
Brain Behav. 2015 Oct 14;5(11):e00402. doi: 10.1002/brb3.402.
43. Social Anxiety Disorder Comorbid with Schizophrenia: The Importance of Screening for This Under recognized and Under treated Condition.
Lowengrub KM, Stryjer R, Birger M, Iancu I.
Isr J Psychiatry Relat Sci. 2015;52(1):40-5
פרקים בספר
1. J.M. Rabey and R. Stryjer.
“The effect of acute loading with selegiline and selegiline and levodopa on blood pressure and plasma norepinephrine levels in chronic Parkinsonian patients”
“Catecholamine Research, from molecular insights to clinical medicine”.
Toshiharu Nagtsu, ToshitakaNabeshima, Richard McCarty and David S. oldstein.
Published by Kluwer Academic/Plenum Publishers.483-486 pp., 2002.
2. R. Stryjer, RD.Strous, R.Shiloh, M. Poyurovsky, A.Weizman
"5HT2a antagonists for the management of neuroleptic induced acute akathisia"
“Focus on Serotonin Uptake Inhibitor Research.”
Nova Science Publishers, Inc.2005
באנציקלופדיה
"Obsessive compulsive disorder" and "paranoia" 600 words each item.
Medical Encyclopedia edited in Israel.
ספרים
R. Shiloh, R. Stryjer, A. Weizman, D. Nutt,
Atlas of Psychiatric Pharmacotherapy, Second Edition
Taylor & Francis Books Ltd. 2005
פרסומים אחרים
1. R.Stryjer.
Case Presentation. MACHBAROT FREUDIANIOT.
Notebook # 11, 82-83 pp., January 2002

לפגישת ייעוץ וטיפול התקשרו: 052-5342757


קליניקה: רחוב הארד 7
בניין הרוויקס קומה שניה
רמת החייל , תל אביב

מלא/י את הטופס ונחזור בייעוץ אדיב ומקצועי

קביעת תורים 24/7 אונליין

Page Reader Press Enter to Read Page Content Out Loud Press Enter to Pause or Restart Reading Page Content Out Loud Press Enter to Stop Reading Page Content Out Loud Screen Reader Support